HighVista Strategies’s Rhythm Pharmaceuticals RYTM Stock Holding History

HighVista Strategies’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Sell	13,657 -3,139	-19%	-$284K	0.35%	87
2026 Q1	$1.46M	Sell	16,796 -26,071	-61%	-$2.54M	0.4%	79
2025 Q4	$4.59M	Buy	42,867 +5,385	+14%	+$571K	1.18%	25
2025 Q3	$3.79M	Buy	37,482 +9,414	+34%	+$874K	0.93%	29
2025 Q2	$1.77M	Sell	28,068 -6,971	-20%	-$427K	0.65%	53
2025 Q1	$1.86M	Sell	35,039 -2,387	-6%	-$132K	0.72%	47
2024 Q4	$2.1M	Hold	37,426	–	–	0.78%	42
2024 Q3	$1.96M	Buy	37,426 +23,064	+161%	+$1.11M	0.68%	46
2024 Q2	$590K	Hold	14,362	–	–	0.22%	114
2024 Q1	$622K	Hold	14,362	–	–	0.22%	110
2023 Q4	$660K	Buy	+14,362	New	+$453K	0.24%	106
2023 Q2	–	Sell	-35,478	Closed	-$633K	–	151
2023 Q1	$633K	Hold	35,478	–	–	0.52%	66
2022 Q4	$1.03M	Buy	+35,478	New	+$912K	0.61%	41
2021 Q2	–	Sell	-24,809	Closed	-$528K	–	136
2021 Q1	$528K	Buy	+24,809	New	+$720K	0.39%	68
2020 Q3	–	Sell	-18,609	Closed	-$415K	–	127
2020 Q2	$415K	Buy	+18,609	New	+$363K	0.34%	57

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

HighVista Strategies's RYTM Position: Q2 2026 in Review

HighVista Strategies reduced its Rhythm Pharmaceuticals (RYTM) stake by 19% in Q2 2026, selling an estimated $284K and leaving 13,657 shares worth $1.52M. The position accounts for 0.35% of the portfolio, ranked #87.

HighVista Strategies first reported a position in RYTM in Q2 2020 and has held it in 15 quarters since. The position peaked at $4.59M in Q4 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

HighVista Strategies held 13,657 shares of Rhythm Pharmaceuticals worth $1.52M as of Q2 2026.
HighVista Strategies sold 3,139 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $284K.
Rhythm Pharmaceuticals made up 0.35% of HighVista Strategies's portfolio in Q2 2026, its #87 holding.
HighVista Strategies first reported a position in Rhythm Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
HighVista Strategies's Rhythm Pharmaceuticals position peaked at $4.59M in Q4 2025.
304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.